Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions

The carcinoembryonic antigen (CEA) serum level tested on January 31, 2013, was 276.37ug/l (the normal value of limitation is 5.0ug/l). Chest Computed tomography (CT) on February 5, 2013, showed a large number of miliary tubercles scattered in two lungs, which like metastatic lesions; one well-defi ned lesion lied in the posterior segment of the right upper lobe, whose edge is not smooth and diameter is about 2cm, among which pleural indentation sign and spicule sign should be found; a few of enlarged lymph nodes located in the mediastinum, among which the maximum diameter is 2.3cm. A CT-guided percutaneous needle biopsy was performed on February 18, 2013, and the pathological fi ndings showed adenocarcinoma. Imaging by PET–CT on February 28, 2013, showed intense fl uorodeoxyglucose activity in the right upper-lobe nodule, SUV max was7.3, diameter was about 2.92cmx2.72cm (Figure 1). Extensive fl uorodeoxyglucose activity was also evident within the following lymph nodes: double hilars, mediastinal, right neck, right subclavian, right upper trachea, retrocaval, and carinal. Of which the SUV max was 12.17 and the maximum diameter is 3.36cmx2.92cm .At the same time, it showed miliary nodules in double lung seem to be metastatic lesions with great possibility. Abstract

At the time of his initial medical oncology consultation, the patient declined chemotherapy and thus was tested for the EGFR mutation in pathological section using the ARMS method. However, he was found to be EGFR mutation-negative (wildtype EGFR). Chemotherapy was offered again, the patient refused once more. Meanwhile,the patient and his families strongly required to try EGFR-TKI treatment. The doctor's persuasion did not work anymore.
First-line therapy with erlotinib was initiated and the patient received his fi rst dose of erlotinib (150 mg daily) on March 31, 2013. Before the treatment, we kept the data about chest CT images and the CEA serum level. The former showed that, compared with the initial CT images acquired on February 5, 2013, the lesion in the right upper lobe had increased in size,which now measured 2.4cmx2.2cm. The latter showed the result was>160.0ng/ml (the normal value limitation is 10.0ng/ ml).On day 9 of erlotinib therapy, he developed a grade 2 rash All lesions in lungs are stable until September 4, 2015, on which the lesion in the right upper lobe had increased in size which now measured 1.9cm×1.7 cm (Figure 4). At the same time, the IL-6 serum level was 7.72ng/l (the normal value is 7.0ng/l). Combination of imaging and IL-6, we speculated that the resistance of EGFR-TKI must be appearance. Therefore, we add metformin (1000mg, twice a day)to reverse the drug resistance. Follow-up CT imaging of the patient's chest on The CEA levels was tested within one month after treatment.
The result was >160ng/ml, 146.88ng/ml, respectively on seventh day and thirtieth day after treatment. The Follow-up result is as table1 fi gure 5.
At the time of March 2016, the patient died in a car accident, even though he was still getting benefi t from erlotinib.
Response to fi rst-line erlotinib in an egfr mutationnegative patient Paez et al. (2004) fi rstly pointed out that some gene mutations may bring benefi t to the effi cacy of EGFR-TKI [1]. The later studies confi rmed the hypothesis and found that the mutations at the exons 18 to 21(especially deletion in exon 19 and missense mutation in exon 21) of the EGFR tyrosine kinase coding region was the strongest predictor of response to TKIs [2][3][4]. Several papers showed that EGFR mutation test should be a prerequisite for fi rst-line treatment of advanced NSCLC with gefi tinib,while a reduction in survival was observed in patients with wild-type EGFR who were given gefi tinib.

Discussion
However, about 70% of lung cancer patients had local invasion or distant metastasis at the time of diagnosis, and surgery was not necessary. So the pathological diagnosis and EGFR gene mutation detection mainly depend on small specimens obtained by percutaneous lung biopsy, transbronchial biopsy, pleural biopsy and so on. But for small  [5] believed that the representativeness of the small sample was poor, which can not refl ect the overall situation of lung cancer. It even lead to erroneous diagnosis sometimes.
They indicated that the main reason underlying this error is the existence of the inherent histologic heterogeneity in a subset of NSCLC. This feature makes lung cancer tissue from small specimens be classifi ed by mistake due to different local structure, squamous cell carcinoma accounted for 10%, adenocarcinoma 14%, large cell carcinoma 50% [6]. Recently, a clinical study of 239 cases of NSCLC patients, compared the clinical small specimens with surgical specimens. The results showed that substantial proportion of the small specimens can not go on EGFR testing or lead the error testing result due to the low proportion of tumor cells [7]. In addition, different detection methods may have great infl uence on the positive rate of EGFR mutations, such as the positive rate is lowest in gene sequencing, which can only detect the specimen with mutation content greater than 30%, even ARMS (amplifi cation refractory mutation system) which had been widely recognized also need the sample containing 1% EGFR mutations among cancer cells to detect [8][9][10]. All of the above factors may lead false negative results in the detection of EGFR gene mutation, which may cause those patients with advanced NSCLC losing the opportunity to receive EGFR-TKI treatment.
Therefore, when the EGFR gene mutation comes out negative, patients surely do not benefi t from EGFR-TKI? In our case report, the NSCLC patient with EGFR negative was treated with erlotinib as the fi rst line therapy, benefi ting 29 months PFS and 36 months OS, which must be longer if there was no accident happend to him. And the side effect is modest. The result about effi cacy of EGFR-TKI in our case is much better than Chemotherapy, and the side effect is more modest than Chemotherapy. In a clinical study of erlotinib, the patient with no EGFR gene mutations or high expression also had good effi cacy [11]. Therefore, it is an urgent problem to fi nd a simple, convenient indicator to predict the EGFR mutation and effi cacy of EGFR-TKI.
In our case, the initial CEA serum level before treatment was >160ng/ml. The vaule was >160 ng/ml, 146.88 ng/ml, repectively on seventh day and thirtieth day after treatment.
CEA directly produced by tumor cells is a clinical common tumor marker. It is closely related to tumor recurrence and metastasis in lung cancer, which also plays certain value of early diagnosis, curative effect evaluation and disease development.
Are there any relationship among CEA level, EGFR mutation and effi cacy of EGFR-TKI?
At present, some studies suggested that serum CEA level was closely related to EGFR mutation of lung adenocarcinoma [12][13][14]. The trial conducted by Pan et al. showed among lung adenocarcinoma patients the serum CEA level in EGFR gene mutation group were signifi cantly higher than the wild.
Conversely, the higher serum CEA level, the more EGFR gene mutation rate [15]. The same conclusion occured in recurrent lung adenocarcinoma patients after surgery [16]. It happens that there is a similar trial completed by Yang et al, which provided a positive correlation between serum CEA expression level and EGFR mutation status in NSCLC patients, namely the EGFR mutation-positive rate increases as the serum CEA expression level rises within a certain range (≥20 ng/mL, especially 20~49 ng/mL) [17]. Shoji et al [13]. Found the EGFR mutation rate is up to 87.5% in recurrent lung adenocarcinoma when the serum CEA≥20ng /ml.  [19]. In particular, CEA response after 4 weeks, defi ned as decline of 50% or more in CEA level, was also predictive for PFS and OS. In summary, elevated serum CEA is a positive predictor for EGFR mutation and the effi cacy of EGFR-TKI; the CEA response can be early predictor of EGFR-TKI outcome in EGFR wild-type.
How did CEA and EGFR generate contact? The downstream molecules of EGFR, such as Akt and STAT, played a key role in the anti-apoptotic pathway [20,21]. The CEA protein had an anti-apoptotic effect, and the question is whether it is also a downstream product of EGFR. Okamoto T [15], speculated the activation of the EGFR transduction pathway, due to gene mutations, might promote the expression of the CEA protein, which is released into the blood. So, if CEA is a signal marker of EGFR gene mutation,its elevated serum concentration is a feature in judging the effi cacy of EGFR-TKI, which needs further basic research and clinical trial experience. Although this mechanism needs further research, but the correlation between the serum concentration of CEA and EGFR gene mutation has been basically established, which provide a simple, noninvasive method to forecast EGFR mutation and effi cacy of EGFR-TKI.
In our case, the side effect specifi c to this class of agents is the development of a rash primarily on the head, face, neck, which occurs after 9 days of treatment. It is similar to the studies, which showed the rash occurs during 1-3 weeks after treatment, reaches maximum intensity after 3-5 weeks, and its incidence rate is 50%-75% [9,22,23]. Multiple trials across different tumour types treated by EGFR inhibitors have  confi rmed a relationship between the incidence and severity of rash with both response and survival. In Study BR.21, it confi rmed these relationships between presence of rash with overall survival increased with rash severity grade: grade 1 versus no rash (HR= 0.41, P < 0.001) and grade ≧2 versus no rash (H= 0.29, P <0.001) [24]. Similar results were observed for PFS and Disease control. In Study PA.3, grade ≧rash (but not grade 1) had a strongly correlation with overall survival improvement: grade≧2 versus no rash (HR=0.47, P <0.001).
In PFS and disease control, it had the similar results [24].
Subgroup analyses from the TRUST study showed PFS and OS were both signifi cantly longer in patients who developed erlotinib-related rash compared to those with no rash [25]. In summary, it appears that patients who develop worse rashes from this class of drugs show more benefi t.
In our case, the SUVmax of the lesions in the posterior segment of the right upper lobe and in the septum is 7.3, 12.17 respectively, which is much higher than the normal value .As we known, 18  But previous studies only focused on the relathionship among one parameter alone with EGFR mutation and effi cacy of EGFR-TKI.As we known, one parameter is not suffi ciently powerful and confi dent for discrimination of false negative EGFR and predicting the effi cacy of EGFR-TKI. Therefore A larger, more comprehensive, multi-institutional study is needed to combine these predictors to evaluate the sensitivity and specifi city of predictors for predicting EGFR mutation.
Make no assumptions. Combination of the clinical predictors of outcome previously reported in the literature should replace one parameter alone even EGFR mutation status to distinguish the person who may benefi t from EGFR-TKI therapy.